To start this activity click Next at the bottom of this page
Release date: October 15, 2013
Expiration date: October 15, 2015
Continue Reading
Estimated time to complete this activity: 54 minutes
This activity is co-provided by the Nurse Practitioner Healthcare Foundation and Haymarket Media Inc.
Statement of need: Lung cancer is the leading cause of cancer death in the United States. Most lung cancer is classified as either non-small cell lung cancer (NSCLC) or small-cell lung cancer (SCLC) for treatment purposes. As with many diseases and disorders, early detection is key to increasing the chances of a successful treatment. Clinician awareness of any new options available for prevention and for screening and treating their patients is essential. The “5As” intervention is designed to help clinicians support their patients in stopping tobacco use. Advances in screening and FDA approval of two new targeted therapies have significantly impacted outcomes for patients with lung cancer. Access to up-to-date and relevant information about these types of options allows clinicians to provide their patients with optimal care.
Target audience: This activity has been designed to meet the educational needs of registered nurses and nurse practitioners involved in the management of patients with cancer.
Educational objectives:
• Describe treatment recommendations for non-small cell and small cell lung cancer
• Describe the 2013 drug approvals, mechanism of action, efficacy, and adverse events for erlotinib and afatinib
• Identify the important therapeutic monitoring for patients treated with erlotinib and afatinib
Accreditation statement: This continuing nursing education activity is provided by the Nurse Practitioner Healthcare Foundation (NPHF).
NPHF is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation statement: Free continuing nursing education credit of 0.75 is available. After reading the article, go to mycme.com to register, take the posttest, and receive a certificate. A score of 80% is required to pass.
Disclosure of conflicts of interest: The Nurse Practitioner Healthcare Foundation (NPHF) assesses conflict of interest with its instructors, planners, reviewers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by NPHF for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. NPHF is committed to providing its learners with high quality CE activities and related materials that promote improvements or quality in health care.
The faculty: Dimpy Mehra, PharmD candidate, and Eshwary Yerramsetty, PharmD candidate, reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.
The planners, reviewers, and staff: Fiona J. Shannon, MHS, FNP; Joyce Pagan; Kristen Childress, DNP, ARNP; Connie Morrison-Hoogstede, MN, ANP, AOCNP; and Genean M. Page, RN, OCN, reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.
Disclaimer: The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of or imply endorsement by Nurse Practitioner Healthcare Foundation, American Nurses Credentialing Center, or Haymarket Media Inc.
As this article contains only a review, participants have an implied responsibility to use this newly acquired information while also consulting other appropriate sources of information in order to gain full understanding of the topic.
HOW TO TAKE THE POST-TEST: To obtain CE credit, please click here after reading the article to take the post-test on myCME.com.
